Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558309 | 0.83 | ALDH1A1 (0.41) | MAPTSMN1; SMN2RAB9AKDM1AMAOA | |
| SCHEMBL7639905 | 0.82 | PSMB8 (0.46) | MAPTSMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL16376509 | 0.79 | MAOB (0.38) | TP53MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL4654972 | 0.78 | NOX1 (0.45) | MAPTSMN1; SMN2NPC1RAB9AMAOA | |
| SCHEMBL30363610 | 0.77 | POLB (0.52) | POLBROCK2TP53MAPTSMN1; SMN2 | |
| SCHEMBL26129284 | 0.77 | NPC1 (0.56) | TP53SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL8975219 | 0.77 | NOX1 (0.66) | POLBROCK2TP53MAPTSMN1; SMN2 | |
| SCHEMBL11982932 | 0.77 | PTGDR2 (0.41) | POLBROCK2TP53MAPTSMN1; SMN2 | |
| SCHEMBL3342299 | 0.77 | MEN1 (0.39) | SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL3427156 | 0.77 | SMN1; SMN2 (0.63) | MAPTSMN1; SMN2ATMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534670-B1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER REC TECH LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7235585-B2 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-30 | — | — | US | disclosed |
| EP-1534670-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004020400-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CNDP2, PNP, APRT | POLB 1440/4885ROCK2 3407/4885TP53 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.